Share-Based Awards Plan (Tables)
|
12 Months Ended |
Dec. 31, 2021 |
| Total Share-Based Compensation Cost Recognized |
The following table summarizes the total share-based compensation cost recognized by the Group:
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
For the years ended December 31, |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
Expensed as cost of revenues |
|
|
327 |
|
|
|
360 |
|
|
|
399 |
|
|
|
62 |
|
Expensed as selling, general and administrative |
|
|
1,768 |
|
|
|
1,897 |
|
|
|
1,840 |
|
|
|
289 |
|
Expensed as research and development |
|
|
3,531 |
|
|
|
4,471 |
|
|
|
4,817 |
|
|
|
756 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
5,626 |
|
|
|
6,728 |
|
|
|
7,056 |
|
|
|
1,107 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Baidu |
|
| Option Activity |
The following table summarizes the option activity for the year ended December 31, 2021:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
remaining contractual life (Years) |
|
|
Aggregate intrinsic value (US$ in millions) |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding, December 31, 2020 |
|
|
24,219,040 |
|
|
|
17 |
|
|
|
7 |
|
|
|
245 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Granted |
|
|
1,299,528 |
|
|
|
17 |
|
|
|
|
|
|
|
|
|
| Exercised |
|
|
(3,040,752 |
) |
|
|
15 |
|
|
|
|
|
|
|
|
|
| Forfeited/Cancelled |
|
|
(1,024,256 |
) |
|
|
14 |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding, December 31, 2021 |
|
|
21,453,560 |
|
|
|
17 |
|
|
|
6 |
|
|
|
84 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vested and expected to vest at December 31, 2021 |
|
|
18,836,432 |
|
|
|
18 |
|
|
|
6 |
|
|
|
69 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercisable at December 31, 2021 |
|
|
14,356,680 |
|
|
|
19 |
|
|
|
5 |
|
|
|
44 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Assumptions Used to Estimate Fair Values of Share Options Granted |
The following table presents the assumptions used to estimate the fair values of the share options granted in the years presented:
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
For the years ended December 31 |
|
| |
|
|
|
|
|
|
|
|
|
| Risk-free interest rate |
|
|
1.58%~2.49% |
|
|
|
1.51~1.52% |
|
|
|
0.63~1.23% |
|
| Dividend yield |
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Expected volatility range |
|
|
34.62%~35.14% |
|
|
|
34.83%~34.92% |
|
|
|
38.12%~39.82% |
|
| Expected life (in years) |
|
|
5.83~6.03 |
|
|
|
5.90~6.01 |
|
|
|
5.80~5.86 |
|
|
| Restricted Shares Activity |
Restricted Shares activity for the year ended December 31, 2021 was as follow:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average grant date |
|
| |
|
|
|
|
|
|
|
|
| Unvested, December 31, 2020 |
|
|
130,501,520 |
|
|
|
16 |
|
| Granted |
|
|
68,985,632 |
|
|
|
23 |
|
| Vested |
|
|
(44,506,528 |
) |
|
|
18 |
|
| Forfeited/Cancelled |
|
|
(16,540,152 |
) |
|
|
17 |
|
| |
|
|
|
|
|
|
|
|
| Unvested, December 31, 2021 |
|
|
138,440,472 |
|
|
|
19 |
|
| |
|
|
|
|
|
|
|
|
|
| iQIYI |
|
| Option Activity |
The following table sets forth the summary of employee option activity under the iQIYI’s 2010 Plan:
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
Weighted average remaining contractual life (Years) |
|
|
Aggregate intrinsic value (US$ in millions) |
|
| Outstanding, December 31, 2020 |
|
|
420,698,274 |
|
|
|
0.49 |
|
|
|
7 |
|
|
|
846 |
|
| Granted |
|
|
2,583,000 |
|
|
|
0.51 |
|
|
|
|
|
|
|
|
|
| Forfeited/Expired |
|
|
(16,151,880 |
) |
|
|
0.51 |
|
|
|
|
|
|
|
|
|
| Exercised |
|
|
(65,463,860 |
) |
|
|
0.43 |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding, December 31, 2021 |
|
|
341,665,534 |
|
|
|
0.49 |
|
|
|
7 |
|
|
|
57 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vested and expected to vest at December 31, 2021 |
|
|
335,342,645 |
|
|
|
0.48 |
|
|
|
7 |
|
|
|
56 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercisable at December 31, 2021 |
|
|
253,949,473 |
|
|
|
0.48 |
|
|
|
6 |
|
|
|
45 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total Share-Based Compensation Cost Recognized |
The following table summarizes the share-based compensation cost recognized by iQIYI:
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
For the years ended December 31, |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
Expensed as cost of revenues |
|
|
171 |
|
|
|
202 |
|
|
|
173 |
|
|
|
27 |
|
Expensed as selling, general and administrative |
|
|
676 |
|
|
|
851 |
|
|
|
718 |
|
|
|
113 |
|
Expensed as research and development |
|
|
238 |
|
|
|
317 |
|
|
|
328 |
|
|
|
51 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
1,085 |
|
|
|
1,370 |
|
|
|
1,219 |
|
|
|
191 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|